Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

True Scientifically well supported Certainty of evidence: high provisional C-CHM-01

Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment.

In short: This claim is correct: anthracyclines and chest radiotherapy can cause chronic, dose-dependent heart damage that may appear years later; at modern doses the absolute risk is lower, and it is monitored and partly preventable.
Conclusion: Anthracycline and chest-radiation cardiotoxicity is real and dose-dependent, and it is monitored and treatable.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

سمية قلبية مزمنة من الأنثراسايكلين

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Anthracycline chemotherapy (and chest radiotherapy) can cause chronic, dose-dependent heart damage that may appear or progress years after treatment.

Origin

Source status
Archive editors
Attribution
Archive editors (rule page summary/narrative)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Claimed mechanism

Myocyte loss; radiation-induced coronary and myocardial damage

Claimed health effect

Heart failure, coronary disease, valvular/pericardial disease

Population concerned

Patients treated with anthracyclines or chest radiotherapy; childhood-cancer survivors

Geographic restriction by Elawady

none found

Scientific assessment

True – The statement is supported by robust evidence.

Certainty of evidence: high – Further research is very unlikely to change the assessment.

1. What was claimed?

Anthracyclines cause chronic cardiotoxicity; late cardiac disease in survivors.

2. What is demonstrably correct?

Correct. Cardiotoxicity occurred in 9% of 2,625 anthracycline-treated patients, mostly within the first year and dose-related (A-CHM-01); childhood survivors show dose-related late cardiac abnormalities and 5-6-fold relative hazards of heart failure versus siblings (A-CHM-02, A-CHM-03).

3. What is wrong or exaggerated?

Nothing material. The archive omits that most early-detected cases recovered fully or partly under heart-failure therapy (11% full, 71% partial; A-CHM-01).

4. What remains unclear?

Absolute long-term risks under current lower-dose protocols: in randomised adjuvant breast cancer trials, adding anthracycline did not increase cardiovascular death within a median 5.4 years (I-CHM-101), whereas at high cumulative doses heart failure was frequent (estimated 26% at 550 mg/m2 doxorubicin; I-CHM-108).

5. Which studies support it?

A-CHM-01, A-CHM-02, A-CHM-03, A-CHM-05 (severe cardiac events 2.9-4.1% with trastuzumab), I-CHM-06 (cardiac mortality RR 1.30 after radiotherapy).

6. Which studies contradict it?

None against the existence of harm; context: benefit evidence I-CHM-01, I-CHM-02.

7. What applies to Germany and Europe?

Cardio-oncology surveillance and prevention are part of European practice: the 2022 ESC cardio-oncology guideline (first ESC guideline on the topic) covers definition, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after treatment (ESC guideline page fetched 2026-10-26; detailed recommendations not audited). Dexrazoxane reduced clinical heart failure in adults by about four-fifths without reducing cancer control (RR 0.22, 0.11-0.43; I-CHM-109).

8. What is known about Egypt?

Anthracyclines and chest radiotherapy are used in Egypt. The Egyptian Society of Cardiology is listed among the national societies endorsing the 2022 ESC cardio-oncology guideline. No Egyptian data on the frequency of cardiotoxicity in patients were found (searches found mainly animal studies).

9. What practical conclusion is appropriate?

Late cardiac effects are a reason for monitoring and prevention, not for refusing curative treatment.

Assessment details

Rationale for certainty of evidence

Consistent prospective and survivorship cohorts with clear dose-response (A-CHM-01, A-CHM-02, A-CHM-03) and randomised-trial data (A-CHM-05, I-CHM-06).

Source quality

Archive editorial summarising peer-reviewed cohorts; numbers checked against abstracts.

Regional transferability

High.

Individual exceptions

Risk higher with higher cumulative dose, young age, pre-existing cardiac risk factors.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: In patients treated with anthracyclines or chest radiotherapy, does treatment cause chronic, dose-dependent cardiac damage that can appear or progress years later, and how large is the absolute risk?

Research question in detail (PECO)
Population
Adults and children treated with anthracyclines and/or chest radiotherapy
Intervention or exposure
Anthracycline chemotherapy (cumulative dose); radiation dose to the heart
Comparison
Lower or no exposure; siblings/general population
Geographic scope
universal biology
Outcomes
  • Heart failure
  • LVEF decline
  • Coronary, valvular, pericardial disease
  • Cardiovascular death

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

  • Chemotherapy for early breast cancer: benefits and risks in 100,000 women

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4 Meta-analysisfull text checkednewly added

    In randomised trials of modern adjuvant regimens, adding anthracycline did not increase cardiovascular death or death without recurrence over a median 5.4 years.

    Actual result
    No significant difference in death without recurrence, including cardiovascular death
    Methodological quality
    high (IPD meta-analysis)
    Relevance
    direct for short-term mortality; does not address late effects
    Limitations
    Short follow-up; high cardiac-risk patients often excluded

    Original publication

  • Can heart damage from anthracyclines be prevented?

    de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2 Meta-analysisabstract checkednewly added

    Dexrazoxane reduced heart failure in adults without reducing cancer control, showing the harm is modifiable.

    Actual result
    RR 0.22 (0.11-0.43)
    Methodological quality
    high (Cochrane, moderate-certainty outcome)
    Relevance
    indirect (limits severity, not existence)
    Limitations
    Paediatric second-cancer signal

    Original publication

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Anthracycline and chest-radiation cardiotoxicity is real, dose-dependent and can appear years later.

Why some studies weigh more

Large cohorts with dose-response and trial-based dose analyses weigh most; the EBCTCG result limits only the size of short-term fatal cardiac risk at modern doses, not the existence of chronic damage.

Is a causal relationship established? Yes, established Consistent dose-response across cohorts and trial arms, biological mechanism, reversibility with prevention (dexrazoxane).

Remaining uncertainty

Absolute lifetime risk under current lower-dose regimens and modern radiotherapy.

Justified conclusion

The claim is correct. Absolute risks depend strongly on dose: several percent at high cumulative doses, low at modern adjuvant doses, and the harm is monitored and partly preventable.

Why do studies seem to disagree?

Cohorts (A-CHM-01..03, I-CHM-108) find frequent cardiotoxicity while EBCTCG 2023 found no excess cardiovascular death. They answer different questions: subclinical/clinical heart dysfunction over many years at higher doses versus fatal cardiac events within about 5 years at modern doses in selected trial patients.

Does this depend on the country?
General biological effects
Universal pharmacology and radiobiology.
Eating habits
Not relevant.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Not relevant.
Actual monitoring data
Egyptian cardiotoxicity research found was mainly animal/mechanistic; no Egyptian incidence data reviewed.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Crude proportion vs model-based cumulative incidence – 32/630 = 5.1% crude; 26% at 550 mg/m2 is a model estimate and cannot be recomputed recalculated
  • Absolute excess from reported prevalences – CHF +1.5, MI +0.5, pericardial +1.0, valvular +1.1 percentage points vs siblings recalculated
  • Log-symmetry of RR 0.22 (0.11-0.43) – Symmetric (0.693 vs 0.670); plausible recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Chronic heart dysfunction/heart failure after anthracyclines
Starting level
low (observational studies)
Reasons for upgrading
  • dose-response
  • large effect (HR about 5 at high doses)
Result
high

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • ESC: 2022 ESC Guidelines on cardio-oncology (with EHA, ESTRO, IC-OS) (2022) · Original publication
    The ESC guideline page states that this first ESC cardio-oncology guideline covers definitions, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after cancer treatment, and that evidence is limited so expert consensus is used where needed. The page lists the Egyptian Society of Cardiology among endorsing national societies. Detailed recommendations (full text, Eur Heart J 2022; PMID 36017568) could not be fetched (HTTP 403) and were not used.
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:"congestive heart failure" AND TITLE:"doxorubicin" AND (TITLE:"retrospective analysis of three trials" OR AUTH:"Swain SM")supporting evidence1
Europe PMC26 October 2026(TITLE:"cardiotoxicity" OR TITLE:"heart failure") AND TITLE:"anthracycline" AND (TITLE:"meta-analysis" OR TITLE:"systematic review") AND (TITLE:"incidence" OR TITLE:"risk") AND PUB_YEAR:[2015 TO 2026]supporting evidence1
PubMed26 October 2026(cardiotoxicity[ti] OR "heart failure"[ti]) AND (anthracycline*[ti]) AND (incidence[ti] OR risk[ti]) AND (meta-analysis[pt] OR systematic review[pt])supporting evidence7
Europe PMC26 October 2026TITLE:"Cardioprotective interventions for cancer patients receiving anthracyclines"contradicting evidence3
Europe PMC26 October 2026TITLE:"dexrazoxane" AND JOURNAL:"Cochrane Database Syst Rev" AND PUB_YEAR:[2012 TO 2026]contradicting evidence1
PubMed26 October 2026"Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp]both directions12
Europe PMC26 October 2026(TITLE:"cardiotoxicity" OR TITLE:"cardiac dysfunction") AND (TITLE:"anthracycline" OR TITLE:"doxorubicin") AND (Egypt OR Egyptian) AND PUB_YEAR:[2015 TO 2026]both directions137
PubMed26 October 2026"cardio-oncology"[ti] AND Lyon AR[au] AND Eur Heart J[ta] AND 2022[dp]guidelines3

Open questions

Lifetime absolute risk with current regimens and cardiac-sparing radiotherapy.

How deeply was this checked?

9 linked studies: 2 checked in full text (1 of them with a structured risk-of-bias assessment), 7 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: True (high)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: True (high)
    New studies quantify (Swain), confirm modifiability (de Baat) and limit short-term fatal risk at modern doses (EBCTCG 2023); they do not change the conclusion.
    New sources: I-CHM-108 I-CHM-109 I-CHM-101

In plain language

Some chemotherapy drugs (anthracyclines) and radiation near the heart can weaken the heart. The risk rises with the dose. Most problems appear in the first year and can often be treated if found early. Survivors of childhood cancer have more heart disease later in life than their siblings. Doctors therefore check heart function during and after treatment.

Studies on this claim

Studies supporting the claim (6)

  • Heart damage after anthracycline chemotherapy is common in the first year

    Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777
    Cohort studycited by the Tayebat archiveabstract checked

    About 9 in 100 patients developed a measurable drop in heart pumping function, mostly within one year; most recovered fully or partly with heart medication.

    Incidence and dose-dependence of cardiotoxicity

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure how often and when anthracyclines damage the heart.

    How was the study done?

    Prospective cohort with repeated echocardiography.

    How many people, animals or samples were studied?

    2,625 patients.

    What was actually found?

    9% cardiotoxicity, 98% within the first year, dose-related.

    How large was the observed effect?

    HR 1.09 per 50 mg/m2 doxorubicin.

    What do the results mean in everyday life?

    Heart monitoring during and after anthracycline therapy is important.

    What are the study's limitations?

    Single centre, no untreated group.

    What does it say about Elawady's specific claim?

    Confirms the harm exists; does not weigh it against cancer-survival benefit.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    That anthracyclines do more harm than good.

    Scientific details →

  • Doxorubicin in childhood can affect heart growth years later

    Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205
    Cohort studycited by the Tayebat archiveabstract checked

    More than half of 115 childhood leukaemia survivors had heart function abnormalities, more often at higher doses.

    Late, dose-related cardiac effects in children

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Assess late heart effects of doxorubicin.

    How was the study done?

    Cardiac testing of survivors.

    How many people, animals or samples were studied?

    115 survivors.

    What was actually found?

    Dose-dependent abnormalities, progressive afterload rise.

    How large was the observed effect?

    65% abnormal at >=228 mg/m2.

    What do the results mean in everyday life?

    Childhood cancer survivors need long-term heart follow-up.

    What are the study's limitations?

    Small, old doses, no control group.

    What does it say about Elawady's specific claim?

    Supports existence of late harm.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Whether leaving leukaemia untreated would be better (it is not).

    Scientific details →

  • Adult survivors of childhood cancer have more heart disease than their siblings

    Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key study

    Survivors reported heart failure about 6 times as often as siblings (1.7% vs 0.2%); by 30 years after diagnosis about 4% had heart failure. Risk rose with anthracycline dose and heart radiation.

    Late cardiac disease

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Quantify late heart disease in survivors.

    How was the study done?

    Retrospective cohort with questionnaires.

    How many people, animals or samples were studied?

    14,358 survivors, 3,899 siblings.

    What was actually found?

    HR 5.9 CHF, 5.0 MI, 6.3 pericardial, 4.8 valvular versus siblings; 30-year cumulative incidence of CHF 4.1%.

    How large was the observed effect?

    Relative hazards 5-6; absolute: CHF in 1.7% of survivors vs 0.2% of siblings.

    What do the results mean in everyday life?

    Lifelong heart follow-up for survivors.

    What are the study's limitations?

    Self-reported, unvalidated diagnoses; possible surveillance bias; few cardiovascular risk factors measured; treatments from 1970-1986.

    What does it say about Elawady's specific claim?

    Supports existence of late harm.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    Absolute risk per patient; that treatment should have been avoided.

    Scientific details →

  • Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk

    Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
    Case-control studycited by the Tayebat archiveabstract checked★ key study

    Each extra Gray of average heart dose increased the rate of major coronary events by about 7%.

    Radiation cardiotoxicity

    Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure heart risk by radiation dose.

    How was the study done?

    Case-control with dose reconstruction.

    How many people, animals or samples were studied?

    2,168 women.

    What was actually found?

    +7.4% per Gy, linear.

    How large was the observed effect?

    ERR 7.4%/Gy (2.9-14.5).

    What do the results mean in everyday life?

    Keep heart dose as low as possible; control cardiac risk factors.

    What are the study's limitations?

    Historical doses; relative measure.

    What does it say about Elawady's specific claim?

    Confirms the archive number.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    That radiotherapy does net harm.

    Scientific details →

  • With modern techniques, radiotherapy's heart and lung risks are small for non-smokers

    Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
    Meta-analysisindependent cross-checkabstract checked★ key study

    About 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.

    Cardiac mortality RR 1.30

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Estimate absolute RT risks.

    How was the study done?

    Dose review + IPD meta-analysis.

    How many people, animals or samples were studied?

    40,781 women.

    What was actually found?

    Small absolute risks; smoking key.

    How large was the observed effect?

    Cardiac mortality RR 1.30.

    What do the results mean in everyday life?

    Stop smoking before/after radiotherapy.

    What are the study's limitations?

    Smoking modelled.

    What does it say about Elawady's specific claim?

    Puts Darby in perspective.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Individual dose-specific risk.

    Scientific details →

  • Heart failure after doxorubicin by dose

    Swain SM et al.. Cancer 2003 · PMID 12767102 · DOI 10.1002/cncr.11407
    Cohort studyindependent cross-checkabstract checked★ key study

    About 5% of 630 patients developed heart failure; risk rose steeply at high cumulative doses (26% estimated at 550 mg/m2).

    Dose-dependent heart failure with doxorubicin.

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Estimate heart failure risk by dose

    How was the study done?

    Re-analysis of three trials

    How many people, animals or samples were studied?

    630 patients

    What was actually found?

    Risk climbs with dose and age

    How large was the observed effect?

    26% at 550 mg/m2 (model estimate)

    What do the results mean in everyday life?

    This is why doctors cap the total dose and monitor the heart

    What are the study's limitations?

    High doses, old trials

    What does it say about Elawady's specific claim?

    Supports the dose-dependence claim

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Cannot give risk for modern low-dose regimens

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (3)

  • Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer

    Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
    Randomised controlled trialcited by the Tayebat archiveabstract checked★ key study

    Fewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.

    Cardiac events 2.9-4.1%

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test trastuzumab added to chemotherapy.

    How was the study done?

    Two RCTs analysed jointly.

    How many people, animals or samples were studied?

    Operable HER2+ breast cancer.

    What was actually found?

    HR 0.48 for events; 33% fewer deaths.

    How large was the observed effect?

    +12% absolute DFS at 3 years.

    What do the results mean in everyday life?

    Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.

    What are the study's limitations?

    Interim analysis.

    What does it say about Elawady's specific claim?

    Documents harm and much larger benefit.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    That treatment should be avoided.

    Scientific details →

  • Chemotherapy for early breast cancer: benefits and risks in 100,000 women

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
    Meta-analysisindependent cross-checkfull text checked★ key study

    Anthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.

    Confirms anthracycline harms are dose-related but found no excess cardiovascular death within about 5 years in trial populations.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Weigh benefits and risks of anthracycline-containing chemotherapy

    How was the study done?

    Pooled individual data from randomised trials

    How many people, animals or samples were studied?

    18,103 women in the main comparison; about 100,000 overall

    What was actually found?

    Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%

    How large was the observed effect?

    10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline

    What do the results mean in everyday life?

    For every leukaemia caused, roughly 18 recurrences are prevented in this data set

    What are the study's limitations?

    Short follow-up for heart effects; high-risk heart patients often excluded

    What does it say about Elawady's specific claim?

    Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Cannot quantify heart failure 15-20 years after treatment

    Scientific details →

  • Can heart damage from anthracyclines be prevented?

    de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2
    Meta-analysisindependent cross-checkabstract checked

    Dexrazoxane cut heart failure in adults by about four-fifths without lowering cancer control.

    Confirms that anthracycline cardiotoxicity is real and shows it can be reduced; supports monitoring/prevention rather than avoidance.

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test a heart-protecting drug

    How was the study done?

    Cochrane review of RCTs

    How many people, animals or samples were studied?

    13 trials, about 2500 patients

    What was actually found?

    Less heart failure in adults

    How large was the observed effect?

    RR 0.22

    What do the results mean in everyday life?

    Heart damage from chemotherapy can be reduced

    What are the study's limitations?

    Weaker evidence in children; possible second-cancer signal

    What does it say about Elawady's specific claim?

    Harm is real but manageable

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Not a reason to avoid treatment

    Scientific details →

Regional context

Germany / EU

Cardio-oncology surveillance and prevention are part of European practice: the 2022 ESC cardio-oncology guideline (first ESC guideline on the topic) covers definition, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after treatment (ESC guideline page fetched 2026-10-26; detailed recommendations not audited). Dexrazoxane reduced clinical heart failure in adults by about four-fifths without reducing cancer control (RR 0.22, 0.11-0.43; I-CHM-109).

Egypt

Anthracyclines and chest radiotherapy are used in Egypt. The Egyptian Society of Cardiology is listed among the national societies endorsing the 2022 ESC cardio-oncology guideline. No Egyptian data on the frequency of cardiotoxicity in patients were found (searches found mainly animal studies).

What applies in my country?

General scientific assessment

True Anthracycline and chest-radiation cardiotoxicity is real and dose-dependent, and it is monitored and treatable.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.. Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777
  2. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.. Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205
  3. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.. Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606
  4. Risk of ischemic heart disease in women after radiotherapy for breast cancer.. Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
  5. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
  6. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.. Swain SM et al.. Cancer 2003 · PMID 12767102 · DOI 10.1002/cncr.11407
  7. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
  8. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
  9. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.. de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2

← Back to overview